TNF and inflammatory bowel disease: In conclusion, we show that the use of TNF-α-antagonists in patients with IBD is strongly associated with an attenuated serological response after full vaccination against SARS-CoV-2, which was independent of the elapsed time since last vaccination and blood sampling, prior SARS-CoV-2 infection, and patient age.